A recent Associated Press analysis reveals continued challenges in the FDA’s ability to oversee global pharmaceutical manufacturing, citing significant inspection delays and a decline in reported violations since the start of the COVID-19 pandemic. The slowdown has raised concerns among lawmakers and public health experts about gaps in drug safety enforcement.

In response to these systemic challenges, Valisure, in partnership with the U.S. Department of Defense, has launched independent testing initiatives to identify quality issues that traditional inspections may miss. A recent pilot study found serious flaws in 10% of tested drug products, highlighting the urgent need for additional safeguards.

Independent lab testing provides a critical layer of protection for the drug supply and reinforces the importance of transparency, accountability, and scientific verification in pharmaceutical quality assurance.

Read the full article via the Associated Press here.

A recent Associated Press analysis reveals continued challenges in the FDA’s ability to oversee global pharmaceutical manufacturing, citing significant inspection delays and a decline in reported violations since the start of the COVID-19 pandemic. The slowdown has raised concerns among lawmakers and public health experts about gaps in drug safety enforcement.

In response to these systemic challenges, Valisure, in partnership with the U.S. Department of Defense, has launched independent testing initiatives to identify quality issues that traditional inspections may miss. A recent pilot study found serious flaws in 10% of tested drug products, highlighting the urgent need for additional safeguards.

Independent lab testing provides a critical layer of protection for the drug supply and reinforces the importance of transparency, accountability, and scientific verification in pharmaceutical quality assurance.

Read the full article via the Associated Press here.